Financial Post
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeting medicine and is an inclusion criterion for ongoing trials BOSTON…
Read More
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
GlobeNewswire
19:55
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeting medicine and is an inclusion criterion for ongoing trials BOSTON…
